Vivosim Labs Inc Quick Ratio (VIVS) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Vivosim Labs Inc   (NASDAQ: VIVS)

Vivosim Labs Inc 's Quick Ratio

VIVS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 0.88 below Vivosim Labs Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 127 other companies have achieved higher Quick Ratio than Vivosim Labs Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 1306 to 1338.

Explain Quick Ratio?
How much Cash & cash equivalents VIVS´s has?
What are VIVS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VIVS Quick Ratio (Jun 30 2026)
Q1		 (Mar 31 2026)
Q4		 (Dec 31 2025)
Q3		 (Sep 30 2025)
Q2		 (Jun 30 2025)
Q1
Y / Y Current Liabilities Change -11.62 % -25.47 % 100.91 % 1.45 % 5.36 %
Y / Y Cash & cash equivalent Change -81.56 % -55.59 % 289.93 % 110.37 % 46.36 %
Quick Ratio MRQ 0.88 1.8 3.03 2.73 4.23
VIVS's Total Ranking # 1338 # 1306 # 1016 # 1279 # 2025
Seq. Current Liabilities Change -32.03 % -25.47 % 52.59 % 14.33 % -42.68 %
Seq. Cash & cash equivalent Change -66.76 % -55.59 % 69.42 % -26.26 % -19.95 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 128
Healthcare Sector # 718
Overall Market # 2517


Quick Ratio Statistics
High Average Low
51.82 12.6 0.67
(Dec 31 2021)   (Dec 31 2012)




Financial Statements
Vivosim Labs Inc 's Current Liabilities $ 2 Millions Visit VIVS's Balance sheet
Vivosim Labs Inc 's Cash & cash equivalent $ 2 Millions Visit VIVS's Balance sheet
Source of VIVS's Sales Visit VIVS's Sales by Geography


Cumulative Vivosim Labs Inc 's Quick Ratio

VIVS's Quick Ratio for the trailling 12 Months

VIVS Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 7 % 10.64 % 47.73 % 2.1 % 10.79 %
Y / Y Cash & cash equivalent TTM Growth -6.65 % 36.03 % 152.96 % 8.64 % -17.38 %
Quick Ratio TTM 2.27 2.89 3.18 2.94 2.6
Total Ranking TTM # 545 # 408 # 474 # 523 # 763
Seq. Current Liabilities TTM Growth -2.24 % -7.89 % 18.42 % 0.34 % 1.09 %
Seq. Cash & cash equivalent TTM Growth -23.03 % -16.39 % 28.09 % 13.25 % 12.17 %

Quick ratio ranking by company, industry and sector >> Back to VIVS Financial Strength Comparisons >> Go to Compare VIVS Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in VIVS's Current Liabilities to $1.89 millions, cumulative Quick Ratio to 2.27 below the VIVS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 156 other companies have achieved higher Quick Ratio than Vivosim Labs Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending fourth quarter 2026 at 4469.

Explain Quick Ratio?
How much Cash & cash equivalents VIVS´s has?
What are VIVS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 157
Healthcare Sector # 976
Within the Market # 1338


trailing twelve months Quick Ratio Statistics
High Average Low
35.41 11.73 1.31
(Dec 31 2021)   (Jun 30 2013)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Kodiak Sciences Inc   2.39 $ 125.903  Millions$ 52.770  Millions
Exelixis Inc   2.32 $ 839.385  Millions$ 361.927  Millions
Precision Biosciences Inc  2.19 $ 87.549  Millions$ 39.886  Millions
Novavax inc   2.18 $ 719.340  Millions$ 330.574  Millions
Regenxbio Inc   2.11 $ 174.530  Millions$ 82.621  Millions
Biocardia Inc   2.00 $ 4.117  Millions$ 2.055  Millions
Kymera Therapeutics Inc   1.75 $ 124.477  Millions$ 71.326  Millions
Biocryst Pharmaceuticals Inc   1.69 $ 353.279  Millions$ 208.846  Millions
Coherus Oncology inc   1.69 $ 127.683  Millions$ 75.510  Millions
Bio techne Corp  1.62 $ 264.712  Millions$ 163.700  Millions
Atara Biotherapeutics Inc   1.45 $ 9.900  Millions$ 6.847  Millions
Twist Bioscience Corporation  1.39 $ 166.839  Millions$ 120.255  Millions
Neumora Therapeutics Inc   1.34 $ 116.834  Millions$ 87.478  Millions
Calidi Biotherapeutics Inc   1.33 $ 4.290  Millions$ 3.237  Millions
Passage Bio Inc   1.17 $ 24.155  Millions$ 20.719  Millions
Mink Therapeutics Inc   1.16 $ 8.807  Millions$ 7.569  Millions
Amgen Inc   1.07 $ 27,404.000  Millions$ 25,502.000  Millions
Aligos Therapeutics Inc   1.07 $ 30.381  Millions$ 28.343  Millions
Vaxart Inc   1.05 $ 77.058  Millions$ 73.108  Millions
Iovance Biotherapeutics inc   1.04 $ 110.768  Millions$ 106.848  Millions
Liminatus Pharma Inc   0.99 $ 3.017  Millions$ 3.040  Millions
Elutia Inc   0.95 $ 19.896  Millions$ 21.045  Millions
Jasper Therapeutics Inc   0.93 $ 7.314  Millions$ 7.845  Millions
Protalix Biotherapeutics inc   0.90 $ 28.140  Millions$ 31.391  Millions
Vivosim Labs Inc   0.88 $ 1.670  Millions$ 1.893  Millions
Senti Biosciences Holdings Inc   0.83 $ 13.124  Millions$ 15.765  Millions
Pelthos Therapeutics Inc   0.78 $ 24.776  Millions$ 31.959  Millions
Ocugen Inc   0.75 $ 100.051  Millions$ 133.080  Millions
Sab Biotherapeutics Inc   0.71 $ 8.267  Millions$ 11.705  Millions
Vaxcyte Inc   0.68 $ 183.190  Millions$ 271.277  Millions

Date modified: 2026-09-26T06:52:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.